The Management of Venous Thromboembolic Disease in Older Adults

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 59, Issue 1, 2004, Pages 34-41

  Rich, Michael W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANABOLIC AGENT; ANTICOAGULANT AGENT; CIMETIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; DALTEPARIN; ENOXAPARIN; ERYTHROMYCIN; FLUCONAZOLE; GEMFIBROZIL; HEPARIN; ISONIAZID; ITRACONAZOLE; METOLAZONE; METRONIDAZOLE; MEVINOLIN; MICONAZOLE; NADROPARIN; NORFLOXACIN; OFLOXACIN; OMEPRAZOLE; PARACETAMOL; PHENYTOIN; PIROXICAM; PROPRANOLOL; TINZAPARIN; UNINDEXED DRUG; WARFARIN;

AGE; AGED; ARTICLE; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC APPROACH ROUTE; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; INCIDENCE; MEDICAL LITERATURE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 0345831907     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/59.1.m34     Document Type: Review

References (70)

1. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S-193S.
2. Berman AR. Pulmonary embolism in the elderly. Clin Geriatr Med. 2001;17:107-130.
3. Goldhaber SZ, Visani L, De Rosa M, for ICOPER. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.
4. Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. The Study of Men Born in 1913. Arch Intern Med. 1997;157:1665-1670.
5. Heit JA, Melton LJ, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs. community residents. Mayo Clin Proc. 2001;76:1102-1110.
6. Guyatt G, Schunëmann H, Cook D, Jaeschke R, Pauker S, Bucher H. Grades of recommendation for antithrombotic agents. Chest. 2001;119:3S-7S.
7. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458-462.
8. Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Haemost. 2001;86:475-487.
9. Stein PD, Gottschalk A, Saltzman HA, Terrin ML. Diagnosis of acute pulmonary embolism in the elderly. J Am Coll Cardiol. 1991;18:1452-1457.
10. Elliott CG, Goldhaber S, Visani L, et al. Chest radiographs in acute pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. Chest. 2000;118:33-38.
11. Rodger M, Makropoulos D, Turek M, et al. Diagnostic value of the electrocardiogram in suspected pulmonary embolism. Am J Cardiol. 2000;86:807-809.
12. Righini M, Goehring C, Bounameaux H, Perrier A. Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med. 2000;109:357-361.
13. Tardy B, Tardy-Poncet B, Viallon A, et al. Evaluation of D-dimer ELISA test in elderly patients with suspected pulmonary embolism. Thromb Haemost. 1998;79:38-41.
14. American Thoracic Society. The diagnostic approach to acute venous thromboembolism. Clinical Practice Guideline. Am J Respir Crit Care Med. 1999;160:1043-1066.
15. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2759.
16. Mayo J, Remy-Jardin M, Muller N, et al. Pulmonary embolism: prospective comparison of spiral CT with ventilation-perfusion scintigraphy. Radiology. 1997;205:447-452.
17. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
18. Glazier RL, Crowell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. JAMA. 1976;236:1365-1367.
19. Mant MJ, Thong KL, Birtwhistle RV, et al. Hemorrhagic complications of heparin therapy. Lancet. 1977;1:1133-1135.
20. Wilson JE III, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med. 1981;70:808-816.
21. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med. 1997;157:2317-2321.
22. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997;157:2562-2568.
23. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
24. Penner JA. Experience with a thrombin clotting time assay for measuring heparin activity. Am J Clin Pathol. 1974;61:645-653.
25. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels: time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475-2479.
26. Kearon C, Johnston M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med. 1998;158:1140-1143.
27. Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Arch Intern Med. 1989;148:1321-1325.
28. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
29. Hirsh J, van Aken WG, Gallus AS. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
30. Campbell NRC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med. 1996;156:857-860.
31. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119:108S-121S.
32. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S.
33. Greinacher A, Völpel H, Janssens U, et al., for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
34. Greinacher A, Janssens U, Berg G, et al., for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593.
35. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation. 1998;98:1575-1582.
36. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
37. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996;100:269-277.
38. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med. 1999;130:800-809.
39. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia (HIT) in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
40. Levine M, Jent M, Hirsh J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
41. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
42. Dunn AS, Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med. 1999;106:660-669.
43. Vigano S, Mannuci PM, Solanis S, et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol. 1984;57:213-220.
44. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997;126:133-136.
45. Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293-1296.
46. Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med. 1982;307:1676-1681.
47. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S-21S.
48. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-460.
49. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH, for the National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970-979.
50. Crowther MA, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998;79:1116-1118.
51. Amesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective trial. Acta Med Scand. 1982;211:65-68.
52. Watz R, Savidge GF. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. Acta Med Scand. 1979;205:293-298.
53. Johanson L, Nylander G, Hedner U, et al. Comparison of streptokinase with heparin: late results in the treatment of deep vein thrombosis. Acta Med Scand. 1979;206:93-98.
54. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
55. Urokinase Pulmonary Embolism Trial. Phase I results: a cooperative study. JAMA. 1970;214:2163-2172.
56. Urokinase Streptokinase Pulmonary Embolism Trial. Phase II results. A cooperative study. JAMA. 1974;229:1606-1613.
57. Goldhaber SZ, Kessler CM, Heit J, et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2:293-298.
58. Dalen JE, Alpert JS. Thrombolytic therapy for pulmonary embolism: is it effective? is it safe? when is it indicated? Arch Intern Med. 1997;157:2550-2556.
59. McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol. 1996;78:469-473.
60. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338:409-415.
61. Greenfield LJ, Rutherford RB. Recommended reporting standards for vena caval filter placement and patient followup: Vena Caval Filter Consensus Conference. J Vasc Interv Radiol. 1999;10:1013-1019.
62. Spence LK, Gironta MG, Malde HM, et al. Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters. Radiology. 1999;210:53-58.
63. Meyer G, Tamisier D, Sors H, et al. Pulmonary embolectomy: a 20 year experience at one center. Ann Thorac Surg. 1991;51:232-236.
64. Gray HH, Morgan JM, Paneth M, et al. Pulmonary embolectomy for acute massive pulmonary embolism: an analysis of 71 cases. Br Heart J. 1988;60:196-200.
65. Ullmann M, Hemmer W, Hannekum A. The urgent pulmonary embolectomy: mechanical resuscitation in the operating theatre determines the outcome. Thorac Cardiovasc Surg. 1999;47:5-8.
66. Timsit J-F, Reynaud P, Meyer G, et al. Pulmonary embolectomy by catheter device in massive pulmonary embolism. Chest. 1991;100:655-658.
67. Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2000;101:893-898.
68. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685-692.
69. Jamieson SW, Auger WR, Fedullo PF, et al. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg. 1993;106:116-126.
70. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 1999;160:523-528.